The Brazil Hepatitis C Drug Market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Hepatitis C is a viral infection primarily affecting the liver, it often leads to cirrhosis and further cirrhosis may develop complications such as liver failure, liver cancer, or oesophageal and gastric varices. The prevalence of this disease is because in early stage of infection, typically it has no symptoms. Critical stage of infection may display symptoms such as fever, dark urine, abdominal pain, and yellow tinged skin occurrence. People with alcoholism and HIV infection of any age group are at increased risk.
Currently, Hepatitis C is a key challenge to public health in Brazil and even WHO is helping the government to drive out this issue.
Market Growth Drivers
The market for hepatitis C is driven by factors such as increase in disease prevalence caused by sharing needles, unsterilized medical equipment, blood transfusion from person, drug abuse and unsafe sex etc
Other prominent factors are- rise in government subsidy and reimbursement by SUS and higher investment in pipeline studies by big players of the market.
High cost of drugs is the top restraint for the market, as it makes the treatment cost much higher and the general population cannot afford it. Exclusivity of American laboratory in the sale of hepatitis C medicine prevents national manufacture and raises price in Brazil.
Due to better screening, drugs are not easily approved in the market, affecting the availability of products in the market and self-imitating nature of the disease in a sizable number of patients are some other primary restraints in the market.